Teva Pharmaceutical Industries Shares Positive Patient Survey Results for AUSTEDO XR …

Teva Pharmaceutical Industries Shares Positive Patient Survey Results for AUSTEDO XR® in Tardive Dyskinesia Treatment

Posted: 20 hours ago / Sept. 21, 2025 2:20 a.m. UTC

TEVA

AUSTEDO XR shows significant movement improvement and high patient satisfaction among tardive dyskinesia patients, according to recent survey results.Quiver AI SummaryTeva Pharmaceuticals has reported positive results from a real-world survey of 209 patients with tardive dyskinesia (TD) who were treated with AUSTEDO XR® (deutetrabenazine) extended-release tablets. Over 94% of patients noted improvement in their movements, with high satisfaction rates (over 89%) regarding the treatment and 96% expressing a desire to continue using it. The survey, presented at the 2025 Psych Congress Annual Meeting, highlighted that many patients experienced enhanced social and emotional well-being due to reduced motor symptoms. AUSTEDO XR is the first FDA-approved treatment for TD, with the company emphasizing its commitment to understanding the lived experiences of those affected by the disorder.Potential PositivesOver 94% of surveyed patients with tardive dyskinesia reported movement improvement after receiving treatment with AUSTEDO XR.High patient satisfaction was reported, with over 89% expressing interest in continuing treatment.96% of patients found AUSTEDO XR easy to take, highlighting its favorable patient experience.Patients experienced improvements in social and emotional well-being due to reduced uncontrollable movements, emphasizing the drug’s impact on quality of life.Potential NegativesThere is a heightened risk of serious side effects, including depression, suicidality, and sedation associated with AUSTEDO XR, which may impact its adoption and acceptance in the market.The press release emphasizes the importance of patient monitoring due to potential adverse effects, which could raise concerns among healthcare providers.Although AUSTEDO XR shows promising survey results, the effectiveness was only based on a survey of 209 patients, which may not sufficiently capture the broader patient experience or outcomes compared to larger clinical studies.FAQWhat is AUSTEDO XR used for?AUSTEDO XR is indicated for the treatment of tardive dyskinesia and chorea associated with Huntington’s disease in adults.How effective is AUSTEDO XR for patients with tardive dyskinesia?Over 94% of surveyed patients reported improved movement after being treated with AUSTEDO XR.What percentage of patients are satisfied with AUSTEDO XR?Approximately 89% of patients reported high satisfaction with AUSTEDO XR treatment.Is AUSTEDO XR easy to take?Yes, more than 96% of patients found AUSTEDO XR easy to take.Where were the survey results presented?The survey results were presented at the 2025 Psych Congress Annual Meeting in San Diego, California.Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.

Receive $TEVA Data Alerts

$TEVA Insider Trading Activity$TEVA insiders have traded $TEVA stock on the open market 6 times in the past 6 months. Of those trades, 1 have been purchases and 5 have been sales.Here’s a breakdown of recent trading of $TEVA stock by insiders over the last 6 months:MARK SABAG (See “Remarks”) sold 337,915 shares for an estimated $6,097,304ELIYAHU SHARON KALIF (EVP, Chief Financial Officer) sold 55,775 shares for an estimated $952,464ERIC A HUGHES (See “Remarks”) sold 52,742 shares for an estimated $799,436MATTHEW SHIELDS (EVP, Global Operations) sold 6,206 shares for an estimated $105,627PLACID JOVER (See “Remarks”) sold 6,053 shares for an estimated $91,748DAVID R. MCAVOY (EVP, Chief Legal Officer) purchased 1,113 shares for an estimated $20,988To track insider transactions, check out Quiver Quantitative’s insider trading dashboard.$TEVA Hedge Fund ActivityWe have seen 249 institutional investors add shares of $TEVA stock to their portfolio, and 306 decrease their positions in their most recent quarter.Here are some of the largest recent moves:FMR LLC removed 24,606,400 shares (-29.7%) from their portfolio in Q2 2025, for an estimated $412,403,264HAREL INSURANCE INVESTMENTS & FINANCIAL SERVICES LTD. added 11,334,780 shares (+51.4%) to their portfolio in Q2 2025, for an estimated $189,970,912PHOENIX FINANCIAL LTD. added 10,296,872 shares (+37.5%) to their portfolio in Q2 2025, for an estimated $172,575,574MENORA MIVTACHIM HOLDINGS LTD. added 9,303,978 shares (+31.9%) to their portfolio in Q2 2025, for an estimated $155,934,671SOUNDWATCH CAPITAL LLC added 8,564,012 shares (+inf%) to their portfolio in Q2 2025, for an estimated $143,532,841ARROWSTREET CAPITAL, LIMITED PARTNERSHIP removed 6,990,407 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $107,442,555POINTSTATE CAPITAL LP added 5,580,910 shares (+36.9%) to their portfolio in Q2 2025, for an estimated $93,536,051To track hedge funds’ stock portfolios, check out Quiver Quantitative’s institutional holdings dashboard.$TEVA Analyst RatingsWall Street analysts have issued reports on $TEVA in the last several months. We have seen 5 firms issue buy ratings on the stock, and 0 firms issue sell ratings.Here are some recent analyst ratings:UBS issued a “Buy” rating on 06/26/2025Goldman Sachs issued a “Buy” rating on 06/06/2025Truist Securities issued a “Buy” rating on 05/28/2025JP Morgan issued a “Overweight” rating on 05/12/2025B of A Securities issued a “Buy” rating on 05/08/2025To track analyst ratings and price targets for $TEVA, check out Quiver Quantitative’s $TEVA forecast page.$TEVA Price TargetsMultiple analysts have issued price targets for $TEVA recently. We have seen 5 analysts offer price targets for $TEVA in the last 6 months, with a median target of $23.0.Here are some recent targets:Ashwani Verma from UBS set a target price of $23.0 on 06/26/2025 Matt Dellatorre from Goldman Sachs set a target price of $24.0 on 06/06/2025 Les Sulewski from Truist Securities set a target price of $25.0 on 05/28/2025 Chris Schott from JP Morgan set a target price of $23.0 on 05/12/2025 Jason Gerberry from B of A Securities set a target price of $22.0 on 05/08/2025 Full Release

Of the 209 patients with tardive dyskinesia (TD) that were surveyed, >94% reported movement improvement once treated with AUSTEDO XR

(deutetrabenazine) extended-release tablets

Patients reported high satisfaction (>89%) with AUSTEDO XR, with 96% expressing interest in continuing t